Further upside potential for ResMed: RBS Morgans

RBS Morgans upgrades ResMed, taking into account greater benefits from Australian dollar tailwinds and skilled management.

ResMed (RMD) shares have more room for gains despite their recent run-up over the past month as the company's earnings strengthen and the Australian dollar provides greater tailwinds, according to RBS Morgans.

The broker upgraded the medical device maker's stock to "outperform" from "neutral", seeing a nearly 10% upside with a target price of $5.97.

While RBS Morgans realises ResMed's prices will further soften in the face of competitive pressures in the US, it thinks the company will be able to deal with this in a variety of ways – given management's ability to maintain margin stability so far – including cost-outs, manufacturing efficiencies and more volume-based deals.

The broker forecasts the benefits from the weakening Australian dollar to contribute 0.7% to the company's gross margin in the first quarter of 2013-14, with greater benefits in the second quarter.

ResMed's forward price-earnings (P/E) ratio at 19 times isn't too demanding "given [the company's] ability to deliver double-digit earnings growth, further increase capital management and gain from an environment where other sectors remain out of favour," according to the broker.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles